Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | FABP2 | P12104 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17831730 | 0.85 | MT-CO2 (0.40) | PTGS1APPPSEN1PSEN2APH1B | |
| SCHEMBL17904517 | 0.78 | APP (0.35) | AKR1C3AKR1C2PTGS1APPPTGS2 | |
| SCHEMBL31240209 | 0.74 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS1CHRM1APP | |
| SCHEMBL1512537 | 0.74 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS1CHRM1APP | |
| SCHEMBL1590709 | 0.74 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS1CHRM1APP | |
| SCHEMBL9558656 | 0.73 | CHRM1 (0.46) | AKR1C3AKR1C2PTGS1CHRM1APP | |
| SCHEMBL30665778 | 0.73 | CYP2D6 (0.42) | MEN1KMT2ALMNAMAPT | |
| SCHEMBL17831661 | 0.73 | CYP2D6 (0.42) | MEN1KMT2ALMNAMAPT | |
| SCHEMBL11188335 | 0.72 | PTGS1 (0.48) | AKR1C3AKR1C2PTGS1CHRM1APP | |
| SCHEMBL9063726 | 0.72 | PTGS1 (0.48) | AKR1C3AKR1C2PTGS1CHRM1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3744713-A1 | DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | Japan Tobacco Inc. (JP) | 2020-12-02 | — | — | EP | disclosed |
| EP-3744713-A1 | DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | Japan Tobacco Inc. (JP) | 2020-12-02 | — | — | EP | disclosed |
| CN-107001286-B | Dihydropyrimidine-2-one compounds and medicinal use thereof | 日本烟草产业株式会社 | 2020-07-07 | — | — | CN | disclosed |
| EP-3231793-B1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | JAPAN TOBACCO INC. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | JAPAN TOBACCO INC. (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-3231793-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2017-10-18 | — | — | EP | disclosed |
| EP-3231793-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| WO-2016093342-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | 日本たばこ産業株式会社 | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | REN, PKD2, ALPI | AKR1C3 3360/4885AKR1C2 2247/4885PTGS1 561/4885 |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | AKR1C3 3360/4885AKR1C2 2247/4885PTGS1 561/4885 |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | AKR1C3 3360/4885AKR1C2 2247/4885PTGS1 561/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | AKR1C3 3360/4885AKR1C2 2247/4885PTGS1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.